NVO:NYSE
Novo Nordisk A/S
38,46 $
arrow_upward
+0,76%(+0,29) 1 d.
24. sept., 10:08:32 GMT-4 · USD
search
Visi simboli
1 d.
5 d.
1 m.
6 m.
Š.g.
1 g.
5 g.
Maks.
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: NVO…
Atvērt
37,95 $
Augsta
38,71 $
Zema
37,92 $
Tirgus kapitalizācija
131,35 mljrd.
Vid. apjoms
12,60 milj.
Apjoms
3,23 milj.
Dividende
4,67%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,59
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,01 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
37,95 $
Augsta
38,71 $
Zema
37,92 $
Tirgus kapitalizācija
131,35 mljrd.
Vid. apjoms
12,60 milj.
Apjoms
3,23 milj.
Dividende
4,67%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 14. aug.
Cenas/peļņas attiecība
9,59
Augstākā 52 ned.
64,16 $
Zemākā 52 ned.
35,12 $
Peļņa uz vienu akciju
4,01 $
Beta
0,73
Apgrozībā esošās akcijas
3,39 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Zacks
·
pirms 16 stundām
Novo Nordisk (NVO) Falls More Steeply Than Broader Market: What Investors Need to Know
Benzinga
·
pirms 17 stundām
QUICK SPARK: Viking Therapeutics Stock Gains 40% in 2 Days
Zacks
·
pirms 23 stundām
Can Novo's Rare Disease Pipeline Add a New Growth Pillar Beyond GLP-1?
Zacks
·
pirms 1 dienas
VKTX Stock Rises on Encouraging Weight-Loss Maintenance Results
Profils
Novo is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s.
Novo employs approximately 48,000 people globally, and markets its products in 168 countries. Novo is controlled by majority shareholder Novo Holdings which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. Wikipedia
Par “Novo Nordisk A/S”
ĢenerāldirektorsMaziar Mike Doustdar
Darbinieki66,7 tūkst.
Dibināšanas datums1923. gada 21. dec.
Galvenais birojsBagsværd, Galvaspilsētas reģions, Dānija
Sektors-
Tīmekļa vietnenovonordisk.com